Effects of a 10-Day Oxytocin Trial in Older Adults on Health and Well-Being

The neuropeptide oxytocin (OT) modulates functioning of the hypothalamic–pituitary–adrenal (HPA) axis and regulates a range of social processes. Clinical studies have used intranasal OT administration to treat symptoms arising from a number of psychiatric disorders including autism, schizophrenia, and depression. Most of this research, however, has been based on single dose treatments of OT in younger adult populations. The present study examined the impact on the health and psychological well-being of a 10-day OT administration in an older adult population. Residentially housed older adults (N = 41, mean age of 80) were enrolled in a randomized, double-blind, placebo-controlled study. Participants received 40 IU intranasal OT or placebo for 10 consecutive days. No changes in mood or cardiovascular states were observed across the 10-day period. Repeated-measures ANOVAs showed that dispositional gratitude improved for the OT infused participants, although gratitude declined for placebo controls over the 10 days (p = .015). Those in the OT condition did not report a decline in physical functioning over time as was observed in the placebo condition (p = .05), and also reported less fatigue compared with controls (p = .03). No significant adverse events were reported throughout the entirety of the study, indicating that OT can be safely used with older adults.

Keywords: oxytocin, intranasal administration, well-being, emotion, older adults

Sociality tends to decline with age (Bassuk, Glass, & Berkman, 1999; Christensen & MacKinnon, 1993; Moody, 2000). In older adults, social isolation is associated with increased morbidity and mortality as well as cognitive decline (Bassuk et al., 1999; Berkman, 1995; Berkman & Glass, 2000; Glass, Mendes de Leon, Marottoli, & Berkman, 1999; Seeman, 1996; Welin et al., 1985; Young & Glasgow, 1998). This results in an unfortunate circumstance: Those with high risk of morbidity and mortality are less likely to sustain the social ties that may improve their general health. The neuropeptide oxytocin (OT) has been hypothesized to lead to social approach-related motivation and behavior (e.g., Kemp & Guastella, 2011). Moreover, laboratory research on healthy adults has found positive effects of OT on factors that may be tied to well-being and social functioning, including reducing levels of anxiety (Heinrichs, Baumgartner, Kirschbaum, & Ehlert, 2003), improving emotional processing (Di Simplicio, Massey-CHASE, Cowen, & Harmer, 2009), and increasing trust (Kosfeld, Heinrichs, Zak, Fischbacher, & Fehr, 2005). Animal and clinical studies suggest that OT possesses mild antipsychotic properties (Caldwell, Stephens, & Young, 2009; Feifel & Reza, 1999; Pedersen et al., 2011), in particular improving symptoms and social functioning in individuals with psychiatric disorders (Feifel et al., 2010; Pedersen et al., 2011). OT is found to be dysregulated in patients with social anxiety disorder (SAD; Hoge, Pollack, Kaufman, Zak, & Simon, 2008) and OT administration produces improvements in mental representations of the self when used as an adjunct to exposure therapy (Guastella, Howard, Dadds, Mitchell, & Carson, 2009). In patients with depressive disorders, significant negative correlations between plasma OT levels and symptoms have been reported (Cyranowski et al., 2013). 

Correspondence concerning this article should be addressed to Paul Zak, Center for Neuroeconomics Studies, Claremont Graduate University, 160 East 10th Street, Claremont, CA 91711. E-mail: paul.zak@cgu.edu
and naturalistic social functioning in a healthy population. The purpose of the present study was to test whether an extended trial of OT would improve social activity as well as state and trait affect in older adults, and to substantiate the safety of OT use in an older adult population. We expected OT to increase social activity in older adults, which could have important benefits on overall health and well-being. In older adults, oxytocin-producing cells in the hypothalamic supraoptic (SON) and paraventricular (PVN) nucleus remain intact (Hofman, 1997) and respond normally to secretory stimuli (Chiodera, Volpi, & Ciord, 1994). The few studies that examine plasma OT in middle to older aged adults indicate that there is little to no variation basal or reactive OT between younger and older populations (Forsling, Montgomery, Halpin, Windle, & Treacher, 1998; Gouin et al., 2010; Taylor et al., 2006). However, little research has examined the effects of OT treatment in older adults, with only handful of studies utilizing very small sample sizes and comprised mostly of middle-aged samples (Epperson, McDougle, & Price, 1996; Pitman, Orr, & Lasko, 1993).

Indeed, very little is currently known about the use of longer-term administration of oxytocin in humans. Experimental studies of the effects of intranasal OT have been conducted in adults with doses between 20 and 264 IU, producing no significant adverse side effects in clinical and healthy populations (MacDonald et al., 2011). However, work on repeated or extended administrations of OT is scarce, with 89% of available literature for review by the authors involving only single treatments of OT. The small number of experiments using repeated OT administrations have used inconsistent samples sizes and dosing procedures (amount, length, intervals) across divergent populations (e.g., den Boer & Westenberg, 1992; Epperson et al., 1996; Feifel et al., 2010; Hollander et al., 2007; Ohlsson et al., 2005; Pedersen et al., 2011). We only found one study reporting that higher doses (40 IU vs. 20 IU) appear to produce larger benefits for schizophrenic symptoms (Feifel et al., 2010). Unlike human studies, there is a substantial body of research on repeated dosing using animal models. Repeated administration (5–14 days), but not single treatments, of OT appears to instigate longer-term benefits for reducing anxiety-like behavior (e.g., Bowen et al., 2011; Slattery & Neumann, 2010), reducing blood pressure (Holst, Uvnas-Moberg, & Petersson, 2002; Peterson, Alster, Lundberg, & Uvnas-Moberg, 1996), and increasing social contact (Bowen et al., 2011; Witt et al., 1992). The present study examines repeated OT administration in a larger sample than previous human studies using a similar time-frame as that used in the animal literature.

Method

Participants

After obtaining Institutional Review Board approval from Claremont Graduate University, 41 participants between the ages of 60 to 95 years old ($M = 80.33, SD = 10.54$) were recruited from two residential senior housing communities in Southern California. A moderate sample size was chosen for this experiment because of the uncertainty regarding the impact of OT drug administration in an older adult population for an extended period of time. All participants were ambulatory at the time of the study. Two participants dropped out of the study voluntarily after Day 1 (baseline), leaving a total sample size of 39 (15 male and 24 female). Random assignment placed approximately half the participants into each group (placebo $n = 18$, OT $n = 21$). The sample was predominantly Caucasian (87%), and the remaining participants were Hispanic (8%), African American (3%), and Asian (2%). The treatment and control groups did not differ significantly in age, the Modified Mini-Mental State exam (MMSE/3MS) scores, or in any other baseline measures.

Materials and Procedure

After obtaining permission from the management of two senior living communities, residents were invited to participate and asked to give written informed consent. The purpose of study was described to potential participants as examining the effect of OT on blood pressure and general health for a 10-day period with a follow-up visit 30 days after commencement. All potential participants underwent a medical screening by a licensed medical doctor prior to enrollment in the study. Exclusion criteria included any acute, unstable, significant, or untreated medical illness, current or recent participation in a clinical trial, kidney insufficiency, unstable blood pressure or heart rate, unexplained fainting, and significant use of vasoconstrictive medications or significant doses of blood pressure medications. The most frequently reported medications were blood pressure and thyroid medications, as well as MVI (multivitamin infusion).

Participants who passed the medical screening were assigned to receive either 40IU of oxytocin (Pitocin) or placebo (saline) by experimenters, following a double-blind design. Doses were administered intranasally once daily for 10 consecutive days. Participants were ambulatory at the time of the study. Two participants were assigned to OT/placebo administration. Surveys were administered and blood pressure was taken on Days 1–10 and after a 20-day washout period (Day 30).

Daily measures. In order to assess additive and sustained effects across days, rather than immediate changes immediately following administration, participants completed mood and sociality measures and had their blood pressure taken daily prior to administration (Days 1–10) and on the Day 30 follow-up. We assessed participants’ mood over the last 24 hours using the Profile of Mood States (POMS), a questionnaire assessing transient mood states, included subscales on tension-anxiety, depression, anger-hostility, vigor-activity, fatigue, and confusion (McNair, Lorr, &
Droppleman, 1971). Participants were also surveyed about their daily engagement in social activities, including those related to interactions with friends and family (e.g., visiting friends and/or family); social-cultural activities (e.g., going to the movies, theaters, concerts, or museums; eating out at restaurants); and organized group events (e.g., book clubs, exercise groups, church services). Daily cardiovascular measures included systolic blood pressure (SBP) and diastolic blood pressure (DBP), recorded non-invasively using an electronic blood pressure cuff.

Psychological and health measures. Participants were asked to complete a number of trait and health-related measures on Day 1 (baseline), Day 10, and Day 30 (follow-up). Trait measures included the Dispositional Gratitude Questionnaire (GQ-6; McCullough, Emmons, & Tsang, 2002), the Satisfaction with Life Scale (Pavot & Diener, 1993), the Affect Intensity Measure (AIM; Larsen, 1984), and the Religious Commitment Inventory (RC10; Worthington et al., 2003). Cognitive and psychological health-related questions came from the Mini-Mental State examination (MMSE; Folstein, Folstein, & McHugh, 1975), the Modified Mini-Mental State examination (3MS; Teng & Chui, 1987), and the Geriatric Depression Scale (GDS; Sheikh & Yesavage, 1986). Additionally, the Short Form Health Survey (SF-36) consisted of 36 questions, yielding an 8-subscale profile of functional health and well-being scores used in subsequent analyses. These subscales included: physical functioning, physical limitations, emotional limitations, energy/fatigue, bodily pain, social functioning, perception of general health, and emotional well-being. Subscale scores ranged from 0 to 100, with higher values representing better function. Additional trait measures of general giving, donations, and volunteering were also assessed in surveys.

Administration procedures. The 40IU dose of OT is the midrange in the pharmacokinetic analysis done by Born et al. (2002) for the closely related peptide arginine vasopressin. Undiluted synthetic OT (brand name Pitocin: Abraxis Pharmaceuticals) was prepared in an intranasal spray bottle on site and kept cold prior to administration. Dosing was performed by a member of the research team between the morning hours of 8:00–10:00 a.m. on each infusion day (Days 1–10) for each participant prior to survey administration. As no human study has yet examined issues related to the duration of OT administration, we selected a conservative length of 10 days.

Results

Reported Side Effects

All reported side effects were minor. Four participants reported adverse side effects 2 to 10 hours after administration. Two of these participants were in the OT condition, reporting drowsiness 2 hours following infusion on Days 2 and 4, separately. One participant in the placebo condition reported congestion and sore throat during the evenings of infusion Days 6 and 7, though neither instance persisted to the next morning. Another participant in the placebo condition dropped out of the study on Day 2 after reporting having a headache and exhaustion from the first infusion. No participants reported any adverse events immediately after infusion. No participants contacted the researchers or a medical doctor for the study at any point during the experiment.

Daily Mood, Social Activity, and Blood Pressure

For the measures taken daily, we were interested in the effect of OT on participants’ moods (POMS), engagement in social activities, satisfaction with social interactions, systolic blood pressure (SBP) and diastolic blood pressure (DBP), and the rate of change in these measures due to the effects of OT over time. A mixed model analysis of variance (ANOVA) analytic strategy was used to test whether the OT and placebo groups (between-groups factor) varied across these variables, using the measures taken on Day 1 (baseline) through Day 10 (within-group factor: 10 levels). We predicted that ratings on the daily measures modeled as separate dependent variables (POMS, engagement in social activities, satisfaction with social activities, SBP, and DBP) would vary as a function of individual-level (each individual compared with themselves across 10 time points) and group-level (OT vs. placebo group) characteristics.

Overall, results from taking this approach produced no meaningful significant effects. For POMS, social functioning, satisfaction with social interactions, and the blood pressure measures (SBP and DBP, see Figure 1), no significant treatment effects were found in any models ($p > .05$). For these measures, no significant treatment by time interactions were found ($p > .05$). Moreover, incorporating age, cohort (living community), or use of antihypertensive drugs as covariates into the models did not yield significant results ($p > .05$). Despite the lack of significant treatment effects, we found a within subject main effect for SBP, $F(1, 24) = 5.49$, $p = .04$, with participants in both conditions appearing to decrease over time showing a significant linear subject trend.

Psychological Well-Being and Subjective Health

A mixed model analysis of variance (ANOVA) analytic strategy was used to test whether the OT and placebo groups varied across multiple trait and health variables, using the measures taken on Day 1 (baseline) and Day 10. These measures included: Gratitude (McCullough et al., 2002), Satisfaction with Life (Pavot & Diener, 1993), Affect Intensity (AIM; Larsen, 1984), Religious Commitment (RC10; Worthington et al., 2003), and Depression (GDS; Sheikh & Yesavage, 1986). Additionally, psychiatric and health measures included the MMSE (Folstein et al., 1975), 3MS (Teng & Chui, 1987), and the Health SF-36, including subscales on physical functioning, physical limitations, emotional limitations, energy/fatigue, bodily pain, social functioning, perception of general health, and emotional well-being.

For trait gratitude, a 2 (treatment: OT/placebo) × 2 (time: Day 1/Day 10) mixed model ANOVA did not find a within subject main effect, $F(1, 37) = .43$, $p = .52$, or treatment effect $F(1, 37) = .11$, $p = .74$, but the interaction was significant $F(1, 37) = 5.49$, $p = .03$, $\eta^2 = .13$. Participants in the OT condition showed a 4% increase in gratitude (Day 1: 5.56, Day 10: 5.79), and those in the placebo condition had a 7% decrease in gratitude (Day 1: 5.98, Day 10: 5.56) from Days 1 to 10 (see Figure 2a). No significant treatment effects were found for satisfaction with life or religious commitment ($p > .05$).

For the Health SF-36 Physical Functioning subscale, a 2 (treatment: OT/placebo) × 2 (time: Day 1/Day 10) mixed model ANOVA did not find a within subject main effect ($p > .05$) and the treatment effect was not significant ($p > .05$); however, the interaction between treatment and time was significant, $F(1, 37) =$
Participants in the OT condition appeared stable in physical functioning (Day 1: 50.13, Day 10: 52.20), and those in the placebo condition experienced a 16% decline in physical functioning (Day 1: 60.87, Day 10: 51.10; see Figure 2b).

For the Health SF-36 Energy/Fatigue subscale, a 2 (treatment: OT/placebo) × 2 (time: Day 1/Day 10) mixed model ANOVA found a significant interaction between treatment and time, \( F(1, 37) = 4.90, p = .03, \eta^2 = .12 \). Participants in the OT condition experienced 7% less fatigue (Day 1: 55.95, Day 10: 51.83), and those in the placebo condition experienced 9% more fatigue over time (Day 1: 53.33, Day 10: 57.96; see Figure 2c).

No significant treatment effects were found on depression, MMSE, or the remaining SF-36 subscales (bodily pain, perception of general health, physical limitations, emotional limitations, emotional well-being, social functioning; \( ps > .05 \)).

**Follow-Up (Day 30)**

After a 20-day washout period (Day 30 of the study), participants had blood pressure taken and completed all study surveys. A mixed model analysis of variance (ANOVA) analytic strategy was used once again to test whether the effects of OT (if any) were sustained after the treatment period, using the measures taken on Day 1 (baseline), Day 10, and Day 30. These analyses revealed no significant differences across all measures between treatment and placebo conditions (\( ps > .05 \)). In the OT condition, the modest improvements in gratitude (Ms Day 1: 5.56, Day 10: 5.79, Day 30: 5.88) and energy/fatigue (Day 1: 55.95, Day 10: 51.83, Day 30: 52.63) appeared to persist at Day 30, but not physical functioning (Day 1: 50.13, Day 10: 52.20, Day 30: 45.89), although no contrasts reached statistical significance.

**Discussion**

The results of this double-blind, placebo-controlled study indicate that a 10-day course of intranasal OT infusion produced no adverse effects and had a mild impact on health and well-being in residentially housed older adults. Our primary hypothesis that OT would increase social activities and engagement was not supported. Gratitude was 11% higher for participants infused with OT compared with those in the placebo condition over the course of the study, although this was mainly driven by a decline in gratitude for the placebo group. Declines in physical functioning that were not observed in the OT condition although the placebo condition reported a 16% decline in physical abilities. In addition, those in the OT condition had 16% less fatigue after the 10-day trial compared with the placebo condition. Depression, social functioning, and all other state and trait affect measures did not vary significantly across conditions. In sum, OT appeared to buffer declines in gratitude, physical functioning, and fatigue observed in the control group.

A large body of research suggests that intranasal oxytocin can increase positive social behavior in the short-term (for reviews see Barraza & Zak, in press; Heinrichs & Domes, 2008). The main prediction that would increase social interaction was not supported. This null result may be in part due to recent evidence indicating that OT infusion does not have generalized effects in humans. Recent studies have suggested that individual differences influence the psychological and behavioral effects of OT infusion. For instance, OT appears to improve the accuracy of inferring the emotional states of others only for those who are inclined to perform poorly (Bartz et al., 2010b). Furthermore, OT has been found to have the opposite effect on some clinical populations,
decreasing trust and cooperation in adults diagnosed with borderline personality disorder (Bartz et al., 2010a) and increasing negative memories of mothers for patients with high attachment anxiety (Bartz et al., 2010c). These findings conflict with the popular notion that OT has broad positive benefits. It should be noted that there was no interaction found in post hoc analyses between adult depression and OT treatment on any of our outcome variables. With a small sample, however, we may not have substantial power to effectively detect an OT by depression interaction. Although our study demonstrates no significant adverse reactions of OT infusion in our sample of older adults, more research is needed to discern whether OT impacts social engagement in everyday life.

That gratitude may be affected after the 10-day OT trial, relative to placebo, is not surprising given the existing literature on the role of oxytocin and empathy (e.g., Barraza & Zak, in press; Rodrigues, Saslow, Garcia, John, & Keltner, 2009; Zak, 2011). There is evidence that gratitude, like empathy, motivates prosocial behavior (Emmons & McCullough, 2003; McCullough et al., 2002). For instance, both empathy and gratitude may have played a role in the evolution of altruism (de Waal, 2008; McCullough, Kimeldorf, & Cohen, 2008). As products of human evolution serving similar evolutionary functions, these emotions potentially share a common neurobiological basis. From a treatment perspective, improving gratitude can itself benefit general well-being in the long-term (Wood, Joseph, & Maltby, 2008; Wood, Joseph, & Maltby, 2009). Moreover, interventions improving gratitude in daily life have been found to improve well-being across multiple measures for both general and clinical samples (Emmons & McCullough, 2003). From a theoretical perspective, these results would lend support to the social approach hypothesis for oxytocin (e.g., Kemp & Guas- tella, 2011). However, gratitude itself was not improved per se. What was observed was a general trend up for the OT condition that was different from a general trend down for the placebo condition, rather than a significant change in gratitude from baseline to Day 10 for the OT group.

The decline in physical functioning (i.e., the impact physical health has on engaging in daily activities) observed in the placebo condition over the 10-day period did not occur for those who received OT. Moreover, OT reduced perceived fatigue. Although a multitude of animal and human studies have implicated OT in the stress response, there is little research indicating that OT is involved in perceived general health. Three studies in humans have shown that some health benefits may arise through stimulation of an immune response. For instance, intravenous OT infusion decreased neuroendocrine and cytokine activation following bacterial endotoxin administration (Clodi et al., 2008). In two other studies, those with the highest levels of endogenous OT after a structured social interaction task showed faster healing of an experimentally induced blister wound, as compared with those with lower OT posttask (Gouin et al., 2010) and OT release after massage was associated with improved immune responses. It is possible that OT may improve fatigue and general physical functioning through action on immune function. Alternative routes exist as OT receptors are present in cardiac tissue (Jankowski et al., 2004) and OT appears to increases both parasympathetic and sympathetic cardiac control (Norman et al., 2010). However, the present study did not examine immune function, nor did we find positive improvements in other general health measures.

Figure 2. Comparison of treatment (OT) and control (placebo) conditions between Day 1 and Day 10 for dispositional Gratitude (A; maximum score = 7), the Health SF-36 Physical Functioning subscale (B; maximum score = 100), and Health SF-36 Fatigue subscale (C; maximum score = 100). Error bars represent the standard error of the mean.
The present study was the first to administer intranasal OT to older adults over an extended period and to directly examine OT’s impact on social functioning and well-being. The results provide evidence that a 10-day course of intranasal OT: (a) produces a few detectable changes in well-being for older adults (maintenance of gratitude and physical functioning, reduced fatigue) and (b) produces no consistent side effects in older adults. The small sample size may have hindered finding a direct effect of OT on social behaviors, and that most of the residents in the study had lived in the facilities for years and had already built social networks. In addition, the measure selected for assessing social behaviors was focused on quantity of social interactions rather than the quality or specific behaviors within the social interactions (e.g., Moskowitz, Pinard, Zuroff, Annable, & Young, 2001). It is possible that OT influences the overall quality of social interaction, rather than the mere quantity. The lack of the trait measures (e.g., gratitude) across the 10-day period also limits interpretation of results. An observable trend across the 10-day period would provide much stronger support for the very modest differences we observed. In addition, our approach had self-report measures completed prior to (rather than after) OT administration. A design where self-reports were taken in the typical 40–60 minutes after OT administration may have produced different results. However, such a design would not be able to disentangle immediate changes in psychological states from longer and more prolonged effects needed to cause sustained changes. This approach was taken in order to assess effects that were less dependent on single OT doses, but longer-lasting changes in mood, health, and social behaviors from repeated OT administration.

Given that there is mounting support for the safe use of OT across all ages and doses (MacDonald et al., 2011), future studies should expand both the populations studied and the sample size. We expect that these findings will encourage researchers to investigate the long-term effect of hormones on social behaviors and well-being. Future research should also vary the dosage and duration of use of OT, and corroborate the positive changes found for psychological and physical well-being evidenced in this study.

References


Received September 6, 2012
Revision received December 6, 2012
Accepted December 7, 2012

ORDER FORM
Start my 2013 subscription to Experimental and Clinical Psychopharmacology® ISSN: 1064-1297
___ $59.00 APA MEMBER/AFFILIATE
___ $185.00 INDIVIDUAL NONMEMBER
___ $624.00 INSTITUTION

In DC and MD add 6% sales tax
TOTAL AMOUNT DUE $______

Subscription orders must be prepaid. Subscriptions are on a calendar year basis only. Allow 4-6 weeks for delivery of the first issue. Call for international subscription rates.

SEND THIS ORDER FORM TO American Psychological Association Subscriptions 750 First Street, NE Washington, DC 20002-4242

Call 800-374-2721 or 202-336-5600
Fax 202-336-5568: TDD/TTY 202-336-6123
For subscription information, e-mail: subscriptions@apa.org

Check enclosed (make payable to APA)
Charge my: □ Visa □ MasterCard □ American Express

Cardholder Name ____________________________
Card No. ____________________________ Exp. Date ____________

Signature (Required for Charge)

Billing Address
Street ____________________________
City ____________________________ State ________ Zip ____
Daytime Phone ____________________________
E-mail ____________________________

Mail To
Name ____________________________
Address ____________________________

City ____________________________ State ________ Zip ____
APA Member # ____________________________

Received September 6, 2012
Revision received December 6, 2012
Accepted December 7, 2012

This document is copyrighted by the American Psychological Association or one of its allied publishers.
This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.